1261570-98-2

Basic information

• Product Name: 2-bromo-5-iodobenzoyl chloride
• Synonyms: 2-bromo-5-iodobenzoyl chloride
• CAS NO: 1261570-98-2
• Molecular Weight: 345.362
• Mol File: 1261570-98-2.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 328.2±27.0 °C(Predicted)
• Density: 2.241±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-bromo-5-iodobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-5-iodobenzoyl chloride(1261570-98-2)
• EPA Substance Registry System: 2-bromo-5-iodobenzoyl chloride(1261570-98-2)

Safety Data

• Hazardous Substances Data: 1261570-98-2(Hazardous Substances Data)

Upstream product

• 25252-00-0 2-bromo-5-iodobenzoic acid 

Downstream Products

• 946525-30-0 4-bromo-3-hydroxymethyl-1-iodo-benzene 
• 1314239-92-3 4-(2-bromo-5-iodobenzyl)phenol 
• 1314239-93-4 2-(4-(allyloxy)benzyl)-1-bromo-4-iodobenzene 
• 1314239-79-6 C₂₃H₂₇BrO₇ 
• 1314239-80-9 C₂₂H₂₅BrO₆ 
• 1314239-81-0 C₃₀H₃₃BrO₁₀ 
• 1314239-82-1 C₃₄H₄₀O₁₀ 
• 1314239-83-2 C₃₅H₄₂O₁₀ 
• 1314239-84-3 C₃₆H₄₄O₁₀ 
• 1314239-91-2 (2-bromo-5-iodophenyl)(4-methoxyphenyl)methanone 
• 1291094-75-1 1-[6-(2-bromo-5-iodo-benzyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-2,2,2-trifluoro-ethanone 
• 1291094-80-8 4-benzyl-6-[2-cyclopropyl-5-((2S,3S,4R,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-benzyl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1291094-69-3 [(2R,3R,4R,5S,6S)-3,4,5-triacetoxy-6-[4-bromo-3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)phenyl]tetrahydropyran-2-yl]methyl acetate 
• 1539295-26-5 1-cyano-2-(4-cyclopropylbenzyl)-4-(β-D-glucopyranos-1-yl)benzene L-proline 

Relevant articles and documents

Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors

Novel C-aryl glucoside SGLT2 inhibitors containing cyclic diarylpolynoid motif were designed and synthesized for biological evaluation. Alkylzinc bromides have been efficiently prepared by the direct insertion of zinc metal into alkyl bromides. The organozinc reagents underwent smooth Pd-catalyzed cross-coupling reactions. Subsequent ring closing metathesis using 2nd generation Grubbs catalyst successfully generated novel class of ansa-compounds. These glucosides with cyclic diarylpolynoids demonstrated moderate in vitro inhibitory activity against SGLT2 in this series to date (IC50 = 59.5-103 nM).

C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHODS THEREOF, AND MEDICAL APPLICATIONS THEREOF

C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of th

TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.